FIPP
NEUTRALFrontier IP Announces CFO Departure
The financial services provider announces the departure of its Chief Financial Officer, who will leave the company by April 2026 to pursue a new opportunity.
Frontier IP Group
20.69GBX
3.44%
Market Cap
14.25M
Volume
40.59k
34% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.26
Day Range
19.00p - 21.00p
52 Week Range
15.55p20.69p30.00p
20.69p
Upcoming Events
FIPP
NEUTRALFrontier IP's portfolio company TVG demonstrates success in animal trials for major livestock disease
The specialist IP commercialisation firm reports that a portfolio company has achieved successful animal trial results for vaccines targeting a major global livestock disease.
FIPP
GOODAmprologix Raises £740,000 in Pre-Series A Funding to Accelerate Novel Antibiotics Development
The biotechnology company has raised £740,000 in a pre-Series A funding round to advance the development of its novel antibiotics, including its lead candidate epidermicin NI01, which is targeting MRSA and other drug-resistant infections.
FIPP
NEUTRALFrontier IP Announces Board Change
The specialist intellectual property commercialisation company announces the departure of its Chief Commercialisation Officer to pursue a new opportunity.
FIPP
NEUTRALFrontier IP Group Plc Announces Holding(s) in Company
The asset management firm has disclosed a change in its shareholding in Frontier IP Group Plc.
FIPP
NEUTRALFrontier IP Group Plc Announces Strategic Partnership for Cambridge Innovation Hub
The specialist in commercialising intellectual property has entered a strategic partnership to develop an innovation hub in Cambridge, aiming to accelerate the scale-up and growth of its portfolio companies.
FIPP
NEUTRALFrontier IP Group signs international distribution deal for Alusid products
The specialist in commercialising intellectual property has announced its portfolio company Alusid has signed a distribution agreement with an Italian firm to expand its sustainable materials across Europe.
FIPP
NEUTRALFrontier IP's portfolio company TVG advances ASF vaccine candidate
The vaccine developer has reached a key milestone in the development of its African Swine Fever vaccine candidate.
FIPP
NEUTRALFrontier IP's portfolio company The Vaccine Group signs option to license agreement with Syva
The animal health company has signed an option to license agreement with Frontier IP's portfolio company to develop a vaccine against a pig disease.
FIPP
NEUTRALFrontier IP Director Completes Share Transaction
The financial services company has disclosed a director's share sale and repurchase transaction.